SciELO - Scientific Electronic Library Online

vol.44 número2Implantación de una campaña de vacunación antigripal en un servicio de farmacia hospitalarioConsenso para identificar los riesgos de los medicamentos peligrosos en los servicios de farmacia hospitalaria índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Farmacia Hospitalaria

versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343


GUISADO-GIL, Ana Belén et al. Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophilcytoplasm antibody associated vasculitides. Farm Hosp. [online]. 2020, vol.44, n.2, pp.46-50.  Epub 28-Set-2020. ISSN 2171-8695.


Patients Included In MAINRITSAN2 trial received either an Individually tailored or a fixed-schedule therapy with rituximab as mainte nance treatment of antineutrophil cytoplasm antibody associated vasculi tides. The aim of this study was to compare the real-world costs of both arms.


We performed a cost-minimization analysis over an 18-month time period, estimating direct costs -drug acquisition, preparation, admi nistration and monitoring costs- from the health system perspective. We conducted a number of additional sensitivity analyses with different as sumptions for unit costs, with further scenarios including the interquartile range of the tailored-infusion group results, different number of monitoring visits for fixed-schedule regimen and different number of reported severe adverse events. A cost-effectiveness analysis was conducted as a sen sitivity analysis using the absolute difference in the relapse rate and its confidence interval.


The individually tailored maintenance therapy with rituximab was shown to be a cost-saving treatment compared to the fixed-schedule therapy (6,049 euros vs. 7,850 euros). Savings resulted primarily from lower drug acquisition costs (2,861 vs. 4,768 euros) and lower preparation and administration costs (892 vs. 1,486 euros), due to the lower number of infusions per patient in the tailored-infusion regimen. The tailoredinfusion regimen presented higher monitoring costs (2,296 vs. 1,596 euros). This result was replicated in all assumptions considered in the sensitivity analysis of cost-minimization approach.


From the perspective of the health system, the tailoredtherapy regimen seems to be the preferable option in terms of direct costs. Further studies assessing all the effects and costs associated to vasculitides maintenance treatment with rituximab are needed to support clinical management and healthcare planning.

Palavras-chave : Rituximab; Antibodies, Antineutrophil Cytoplasmic; ANCA associated vasculitides; Pharmacoeconomy.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )